Novo Allé
Bagsvaerd , 2880
Bagsvaerd , 2880
News
-
Novo Nordisk AS jumped 3.4% to $96.34 after the Danish company said it will stop kidney trials earlier because of promising results.
The company's drug therapy Ozempic uses active ingredient semaglutide, which the company also uses in the making of its weight-loss drug Wegovy.
After the Novo Nordisk's news, Davita Inc plunged 18% to $54.58 and Fresenius Medical Care dropped 16.7% to $17.45.
Oct 11, 2023
Executive/
Director
Links
Price
- Last Close
-
$ 137.51
$ +4.29 3.22 %
Aug 29, 2024
- 52-Week High/Low
- $199.5 - $87.75
- YTD
- 32.9%
- Trading Volume
- 111,337
- Market Cap Full
- $
- Shares Outstanding
-
Jan 1, 1970
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Q1 | - | -5.1% | -2.5% | -6.7% | 13.5% | -5% | -3.5% | -0.6% | 17.6% | 24.1% |
| Q2 | 2.6% | -0.8% | 25.1% | -4.7% | -2% | 4% | 24.3% | -0.2% | 1.7% | -0.9% |
| Q3 | -1% | -21.9% | 13.4% | 1.8% | 0.2% | 8% | 15.1% | -10.6% | -43.8% | - |
| Q4 | 7.1% | -13.8% | 9.7% | -1.1% | 11.7% | 0.6% | 16.5% | 35.8% | 12.7% | - |
| J | F | M | A | M | J | J | A | S | O | N | D | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | 10.9% | 4.4% | 7.2% | -1.5% | - | - | - | - | - | - | - | - |
| 2023 | 2.5% | 1.6% | 12.8% | 5% | -3.9% | 0.8% | -0.4% | 15.3% | -51% | 6.1% | 5.5% | 1.6% |
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0% | 0% | -37% | 54% | -12% | 25% | 21% | 61% | 21% | -24% | 33% |
Earnings
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|
| Q1 | 0.45 | 0.55 | 0.58 | 0.73 | 0.66 | 0.75 | 0.88 | 0.94 | 0.63 |
| Q2 | 0.48 | 0.60 | 0.59 | 0.68 | 0.61 | 0.67 | 0.85 | 0.84 | 0.63 |
| Q3 | 0.49 | 0.58 | 0.62 | 0.58 | 0.64 | 0.69 | 0.84 | 0.86 | 0.73 |
| Q4 | 0.47 | 0.50 | 0.53 | 0.44 | 0.55 | 0.65 | 0.73 | 0.41 | - |
| A | 1.9 | 2.2 | 2.3 | 2.4 | 2.5 | 2.8 | 3.3 | 3.05 | 1.99 |
Annual Returns
52 Week
High/Low
Annual
Earnings
Chart
Trading Volume
Dividend +
Dividend +
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Q1 | 0.56 | 0.56 | 0.66 | 0.74 | 0.85 | 0.66 |
| Q2 | 0.32 | 0.37 | 0.39 | 0.41 | 0.31 | 0.37 |
| Q3 | - | - | - | - | - | - |
| Q4 | - | - | - | - | - | - |
| A | 0.88 | 0.93 | 1.05 | 1.15 | 1.16 | 1.03 |
Outstanding Shares
(In Millions) +
Jan 16, 2024
| Mar |
| Jun |
| Sep |
| Dec |
Annual
SEC Filings
Financial Ratios
| 2022 | 2021 | 2020 | 2019 | 2018 | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Management | ||||||||||||||||||
| Inventory / Stock Turnover | 1.2 | 1.2 | 1.1 | 1.1 | 1.1 | |||||||||||||
| Fixed Asset Turnover | 2.6 | 2.5 | 2.5 | 2.3 | 2.6 | |||||||||||||
| Total Asset Turnover | 0.7 | 0.7 | 0.9 | 1 | 1 | |||||||||||||
| Leverage | ||||||||||||||||||
| Debt Ratio | 0.2 | 0.2 | - | 0.1 | - | |||||||||||||
| Debt – Equity Ratio | 0.3 | 0.2 | 0.1 | 0.1 | - | |||||||||||||
| Interest Coverage | 3.9 | 5.4 | 4.5 | 3.9 | 5.5 | |||||||||||||
| Equity multiplier | 0.8 | 0.8 | 0.8 | 0.9 | 0.8 | |||||||||||||